Reaction mass of 2-ethyl-2-[[3-(2-methylaziridin-1-yl)propionyl]methyl]propane-1,3-diyl bis(2-methylaziridine-1-propionate) and 2,2-bis({[3-(2-methylaziridin-1-yl)propanoyl]oxy}methyl)butyl 3-[2,2-bis({[3-(2-methylaziridin-1-yl)propanoyl]oxy}methyl)butoxy]propanoate

Sensitisation data (human)

Administrative data

Endpoint:

sensitisation data (humans)

Type of information:

other: case reports

Adequacy of study:

supporting study

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: Short communication. Case reports and patch testing.

Data source

Reference

Reference Type:

publication

Title:

Allergic contact dermatitis from aziridine crosslinker

Author:

Ibbotson SH and Lawrence CM

Year:

1994

Bibliographic source:

Contact Dermatitis; 30: 306

Materials and methods

Type of sensitisation studied:

skin

Study type:

case report

Principles of method if other than guideline:

Patch testing

Test material

Test material information

Constituent 1

Reference substance name:

2-ethyl-2-[[3-(2-methylaziridin-1-yl)propionyl]methyl]propane-1,3-diyl bis(2-methylaziridine-1-propionate)

EC Number:

264-763-3

EC Name:

2-ethyl-2-[[3-(2-methylaziridin-1-yl)propionyl]methyl]propane-1,3-diyl bis(2-methylaziridine-1-propionate)

Cas Number:

64265-57-2

Molecular formula:

C24H41N3O6

IUPAC Name:

2-ethyl-6-(2-methylaziridin-1-yl)-2-({[3-(2-methylaziridin-1-yl)propanoyl]oxy}methyl)-4-oxohexyl 3-(2-methylaziridin-1-yl)propanoate (non-preferred name)

Method

Type of population:

occupational

Clinical history:

Case number 1:
A 43-year-old man presented with a 6-month history of a rash on his face, arms and body. He had worked as a water-based printer for 27 years, but commenced work at his current employment 7 months prior to the onset of skin problems. He first noticed a rash on his fingers and wrists, initially partially responsive to topical corticosteroids, but subsequently spreading to his legs, arms and trunk over a 2-month period. The rash improved whilst off work, but recurred within 2 days of return. He had no history of atopy or skin disorder and was receiving no medication. Examination revealed a severe, acute, vesicular eczema of the dorsum and palms of the hands, fingers, head and neck. There was no sparing of light-protected areas and eczema was evident on the flank, thighs adjacent to the pockets and left great toe.

Case number 2:
A 57-year-old man presented with a 5-month history of a rash on his face, limbs and body. He had worked as a printer all his adult life and joined his present employment 5 months prior to the onset of the rash. Skin involvement was first noticed on the dorsum of the
fingers and on the wrists. This improved whilst he was on holiday and during periods away from work and recurred on return, worsening and spreading to the head, neck and trunk. He was otherwise well, without any history of atopy or skin disorder and receiving no medication. On examination, eczema of the upper and lower arms, hands, fingers, trunk, head and neck was evident.
Light-protected areas were not spared and the sides of the thighs were involved, although the skin under the underpants was spared.

Route of administration:

dermal

Details on study design:

Patch testing
In each case, patch tests were performed to the Europe standard series, a face and an industrial series. Case number 1 reacted to thiuram mix (1.0% pet.) and had worn rubber gloves in the factory. Patch tests were also performed to ingredients of the water-based inks, including dimethylaminoethanol (0.01, 0.1, 1.0% aq.) and crosslinker (0.1% aq.). Both men gave positive reactions to crosslinker at 3 days, on both back and upper arm sites.

Applicant's summary and conclusion

Conclusions:

Patch tests were performed to the Europe standard series, a face and an industrial series. Case number 1 reacted to thiuram mix (1.0% pet.) and had worn rubber gloves in the factory. Patch tests were also performed to ingredients of the water-based inks, including dimethylaminoethanol (0.01, 0.1, 1.0% aq.) and crosslinker (0.1% aq.). Both men gave positive reactions to crosslinker at 3 days, on both back and upper arm sites.